Review of integrated mental health and substance abuse treatment for patients with dual disorders
- PMID: 9853791
- DOI: 10.1093/oxfordjournals.schbul.a033351
Review of integrated mental health and substance abuse treatment for patients with dual disorders
Abstract
Patients with severe mental disorders such as schizophrenia and co-occurring substance use disorders traditionally received treatments for their two disorders from two different sets of clinicians in parallel treatment systems. Dissatisfaction with this clinical tradition led to the development of integrated treatment models in which the same clinicians or teams of clinicians provide substance abuse treatment and mental health treatment in a coordinated fashion. We reviewed 36 research studies on the effectiveness of integrated treatment for dually diagnosed patients. Studies of adding dual-disorders groups to traditional services, studies of intensive integrated treatments in controlled settings, and studies of demonstration projects have thus far yielded disappointing results. On the other hand, 10 recent studies of comprehensive, integrated outpatient treatment programs provide encouraging evidence of the programs' potential to engage dually diagnosed patients in services and to help them reduce substance abuse and attain remission. Outcomes related to hospital use, psychiatric symptoms, and other domains are less consistent. Several program features appear to be associated with effectiveness: assertive outreach, case management, and a longitudinal, stage-wise, motivational approach to substance abuse treatment. Given the magnitude and severity of the problem of dual disorders, more controlled research on integrated treatment is needed.
Similar articles
-
Closing service system gaps for homeless clients with a dual diagnosis: integrated teams and interagency cooperation.J Ment Health Policy Econ. 2003 Jun;6(2):77-87. J Ment Health Policy Econ. 2003. PMID: 14578540
-
Treatment for dual diagnosis patients in the psychiatric and substance abuse systems.Ment Health Serv Res. 2005 Dec;7(4):229-42. doi: 10.1007/s11020-005-7455-9. Ment Health Serv Res. 2005. PMID: 16320106
-
Substance abuse with mental disorders: specialized public systems and integrated care.Health Aff (Millwood). 2006 May-Jun;25(3):648-58. doi: 10.1377/hlthaff.25.3.648. Health Aff (Millwood). 2006. PMID: 16684728
-
[Personality disorders and substance abuse disorders. Psychosocial strategies].Actas Esp Psiquiatr. 2001 Jan-Feb;29(1):58-66. Actas Esp Psiquiatr. 2001. PMID: 11333520 Review. Spanish.
-
Psychosocial approaches to dual diagnosis.Schizophr Bull. 2000;26(1):105-18. doi: 10.1093/oxfordjournals.schbul.a033429. Schizophr Bull. 2000. PMID: 10755672 Review.
Cited by
-
Integrated Dual Disorder Treatment Implementation in a Large State Sample.Community Ment Health J. 2017 Apr;53(3):358-366. doi: 10.1007/s10597-016-0019-1. Epub 2016 May 28. Community Ment Health J. 2017. PMID: 27234036
-
Psychometric properties of the transaddiction craving triggers questionnaire in alcohol use disorder.Int J Methods Psychiatr Res. 2020 Mar;29(1):e1815. doi: 10.1002/mpr.1815. Epub 2019 Dec 29. Int J Methods Psychiatr Res. 2020. PMID: 31884724 Free PMC article.
-
Perceptions of mental health and substance abuse program administrators and staff on service delivery to persons with co-occurring substance abuse and mental disorders.J Behav Health Serv Res. 2004 Jan-Mar;31(1):38-49. doi: 10.1007/BF02287337. J Behav Health Serv Res. 2004. PMID: 14722479
-
Organizational factors influencing implementation of evidence-based practices for integrated treatment in behavioral health agencies.Psychiatry J. 2014;2014:802983. doi: 10.1155/2014/802983. Epub 2014 Mar 3. Psychiatry J. 2014. PMID: 24772411 Free PMC article.
-
Protocol of a randomized controlled trial examining psychosocial enhancement and standard medication treatment for co-occurring opioid use and mental health disorders: A half fractional factorial randomized controlled trial.Contemp Clin Trials. 2024 Oct;145:107668. doi: 10.1016/j.cct.2024.107668. Epub 2024 Aug 18. Contemp Clin Trials. 2024. PMID: 39163904